Biomarkers in Amyotrophic Lateral Sclerosis is focused on the biomarker identification and development in patients with Amyotrophic Lateral Sclerosis (ALS). This report focuses on the ALS space featured in the parent report, highlighting several biomarker targets under investigation and the progress that has been made in the industry. With regards to employing the use of biomarkers for Amyotrophic Lateral Sclerosis, Biomarkers in Amyotrophic Lateral Sclerosis captures market growth of biomarkers, advantages, disadvantages, and validation techniques.
Experts interviewed in this report include:
- Dr. Merit Ester Cudkowicz, Chief of Neurology at Massachusetts General Hospital
- Dr. Andreas Jeromin, CSO and President of Atlantic Biomarkers
Also available in this report is extensive survey data exclusively conducted for this report. Illustrated by 30 figures captured by an in-depth analysis, this section features insight into targets under investigation, challenges, advantages, and desired features of future diagnostic applications.
Insight Pharma Reports also engineered a table of clinical trial information and pipeline data from multiple databases related to ALS. This table features companies, targets, clinical phases, and brief target/product descriptions.